One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Duchenne Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Del-zota for Duchenne muscular dystrophy (exon 44 skipping) in an undisclosed window, under a BLA from Novartis.
What the FDA is deciding on Del-zota for Duchenne muscular dystrophy
The FDA is reviewing Novartis' application to approve Del-zota (delpacibart zotadirsen) for Duchenne muscular dystrophy (exon 44 skipping).
Antibody-linked exon 44 skipping therapy designed to carry the drug into skeletal and heart muscle, for people with Duchenne whose mutations are amenable to exon 44 skipping. The FDA accepted the application for priority review under the accelerated approval pathway, based on the Phase 1/2 EXPLORE44 trial and its open-label extension; a global Phase 3 trial now underway is the confirmatory study.
Novartis disclosed the acceptance on September 8, 2026 but has not disclosed a target action date.
Who the Del-zota decision matters to
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscle fibers from damage.
Without it, muscles deteriorate and are gradually replaced by fat and scar tissue. Multiple exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen) have FDA accelerated approval.
More about Duchenne Muscular Dystrophy
Delandistrogene moxeparvovec (Elevidys), the first gene therapy for DMD, received accelerated FDA approval in June 2023. In June 2024 the FDA granted traditional approval for ambulatory patients (those who can walk) aged 4 and older and accelerated approval for non-ambulatory patients.
After 2 deaths from acute liver failure in non-ambulatory patients, the FDA announced an investigation in June 2025, and in July 2025 it asked Sarepta to pause all shipments; on July 28, 2025 it recommended that treatment of ambulatory patients resume. In November 2025, the FDA added a boxed warning (its most serious warning) for acute serious liver injury and acute liver failure, including deaths, and limited the indication to ambulatory patients aged 4 and older, so Elevidys is no longer approved for non-ambulatory patients.
Prevalence: 1 in 3,500 to 5,000 male births. See our full Duchenne Muscular Dystrophy page for current treatments, recruiting trials, and community resources.
How Del-zota works
Del-zota: antibody to transferrin receptor 1 linked to a morpholino oligonucleotide (PMO) that makes muscle cells skip exon 44 of the dystrophin gene. Our full Del-zota profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Del-zota would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Duchenne Muscular Dystrophy treatment stands today
Read our full Duchenne Muscular Dystrophy treatment summary
DMD research is remarkably active, with multiple exon-skipping therapies approved or in advanced trials, offering hope for slowing or stabilizing disease progression.
Two newer oral medicines are FDA approved for DMD regardless of the specific mutation: vamorolone (Agamree), a once-daily corticosteroid liquid approved in October 2023 for patients 2 years and older, and givinostat (Duvyzat), a twice-daily histone deacetylase (HDAC) inhibitor liquid that targets inflammation and muscle loss, approved in March 2024 for patients 6 years and older.
The FDA has 4 pending Duchenne decisions as of November 7, 2026. Capricor's cell therapy deramiocel, for upper limb (arm and hand) function, has a decision date of November 22, 2026.
Dyne's zeleciment rostudirsen, an exon 51 skipping drug given once every 4 weeks, has a decision date of January 21, 2027. Novartis's del-zota (delpacibart zotadirsen), for people amenable to exon 44 skipping, is under priority review with no date made public.
Sarepta's request to convert Amondys 45 and Vyondys 53 to traditional approval has a decision date of February 28, 2027, and according to Parent Project Muscular Dystrophy both drugs remain available under their accelerated approvals during that review. An application under review is not an approval.
Gene therapy approaches are expanding, and newer antisense oligonucleotides are being tested for additional dystrophin mutations. The Muscular Dystrophy Association maintains a comprehensive trial database.
These advances are most impactful when started early, so if you have a recently diagnosed child, discuss with your neurologist which newer therapies might be appropriate and monitor emerging trial opportunities.
Genetic testing to identify your specific dystrophin mutation can help determine which targeted therapies you're eligible for.
The Duchenne Muscular Dystrophy page has every treatment and trial →Meanwhile, 76 Duchenne Muscular Dystrophy studies are recruiting or not yet recruiting
Whatever the FDA decides here, research on Duchenne Muscular Dystrophy does not stop. The most recently updated:
Earlier-stage drugs Trial Friend tracks for Duchenne Muscular Dystrophy
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Duchenne Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
When will the FDA decide on Del-zota?
Novartis has not disclosed a decision date.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
What is Del-zota being reviewed for?
Novartis submitted a BLA for Del-zota in Duchenne muscular dystrophy (exon 44 skipping).
What to know: Antibody-linked exon 44 skipping therapy designed to carry the drug into skeletal and heart muscle, for people with Duchenne whose mutations are amenable to exon 44 skipping. The FDA accepted the application for priority review under the accelerated approval pathway, based on the Phase 1/2 EXPLORE44 trial and its open-label extension; a global Phase 3 trial now underway is the confirmatory study. Novartis disclosed the acceptance on September 8, 2026 but has not disclosed a target action date.
How it works: Antibody to transferrin receptor 1 linked to a morpholino oligonucleotide (PMO) that makes muscle cells skip exon 44 of the dystrophin gene.
More: the Del-zota drug page explains it in plain language.
Is there already an FDA-approved treatment for Duchenne Muscular Dystrophy?
Yes. Trial Friend's drug list includes 8 FDA-approved drugs for Duchenne Muscular Dystrophy.
Approved: Exondys 51 (eteplirsen), Emflaza (deflazacort), Vyondys 53 (golodirsen), Viltepso (viltolarsen), Amondys 45 (casimersen), Elevidys (delandistrogene moxeparvovec), Agamree (vamorolone), Duvyzat (givinostat).
Also coming: Deramiocel, Zeleciment rostudirsen.
Check: the Duchenne Muscular Dystrophy page also searches FDA drug labels for approved treatments.
What did the Del-zota trials show?
EXPLORE44 (NCT05670730) was a Phase 1/2 trial. Its Part B randomized 26 males with DMD44 aged 7 to 27, at 10 US sites, 3 to 1 to del-zota (9 at 5mg/kg, 10 at 10mg/kg) or placebo (7); its main measure was safety.
More: the Del-zota drug page has the full trial history and sources.
What are the side effects of Del-zota?
Del-zota has no FDA label yet, so the full list of side effects and warnings is not set. In the placebo-controlled part of EXPLORE44, 16 of 19 participants on del-zota (84%) and 6 of 7 on placebo (86%) had at least 1 side effect, most of them mild or moderate.
More: the Del-zota drug page has the safety details reported so far.
Can I get Del-zota before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 76 Duchenne Muscular Dystrophy studies are recruiting or not yet recruiting. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Novartis directly. Registered programs are listed on ClinicalTrials.gov.
How much will Del-zota cost?
Novartis has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Del-zota decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Novartis community letter via PPMD. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.